Revolutionizing
Drug Delivery Systems
About
Synth-Med is an early-stage company revolutionizing the delivery of efficacious drugs to difficult to target tissues.
We are leveraging the unique properties of red blood cells (RBCs), the body’s most abundant and naturally biocompatible carriers. RBCs have low immunogenicity and an exceptionally long circulation half-life, making them ideal for therapeutic delivery.
Synth-Med is led by an multidisciplinary team with deep expertise in drug development, pharmacology and biophysics.
Platform
Our platform enables precisely targeted delivery of a range of therapeutic modalities. Our lead asset delivers a memory-enhancing molecule to the brain, addressing a critical unmet need in Alzheimer’s disease and opens new frontiers in treatment of neurodegenerative disease.
Our proprietary process encapsulates a therapeutic payload within a nanoparticle composed of a native proteome and lipidome.
A final component is the inclusion of an exquisite targeting system for therapeutic delivery.
Pipeline
Synth-Med’s technology can deliver a memory enhancing compound into the brain. Mouse models of Alzheimer’s Disease show an improved memory when treated with our technology.
We see deep potential in this technology, and are building therapeutic particles that have efficacy in additional disease areas.
Contact
contact@synth-med.com
Synth-Med Biotechnology Inc.
MaRS Centre, West Tower
661 University Avenue, Suite 1300
Toronto, Ontario, Canada M5G 0B7
Synth-Med Biotechnology 